Expression of 17-1A Antigen and Complement Resistance Factors CD55 and CD59 on Liver Metastasis in Colorectal Cancer

Journal of Gastrointestinal Surgery

Volumn 5, Issue 6, 2001, Pages 673-679

  Hosch, Stefan B ^a   Scheunemann, Peter ^a   Lüth, Manuel ^a   Inndorf, Stefan ^a   Stoecklein, Nikolas H ^a   Erbersdobler, A ^a   Rehders, Alexander ^a   Gundlach, Mat ^a   Knoefel, Wolfram T ^a   Izbicki, Jakob R ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

17 1A; Colorectal cancer; Complement resistance factors; Liver metastases

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; CARCINOMA; CHI SQUARE DISTRIBUTION; COLORECTAL TUMOR; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; CULTURE TECHNIQUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LIVER TUMOR; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROBABILITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD55; ANTIGENS, CD59; ANTIGENS, NEOPLASM; CARCINOMA; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; COMPLEMENT ACTIVATION; CULTURE TECHNIQUES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROBABILITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0035502376     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(01)80111-6     Document Type: Article

References (35)

1. Taylor I. Liver metastases from colorectal cancer: Lessons from past and present clinical studies. Br J Surg 1996;83:456-460.
2. Steele G, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Ann Surg 1989;210:127-138.
3. Sinnige HA, Mulder NH. Colorectal carcinoma: An update. Neth J Med 1991;38:217-228.
4. Winawer SJ, Zauber AG, Stewart E, O'Brien MJ. The natural history of colorectal cancer. Opportunities for intervention. Cancer 1991;67:1143-1149.
5. Greenwald P. Colon cancer overview. Cancer 1992;70:1206-1215.
6. Greenson JK, Isenhart CE, Rice R, et al. Identification of occult micrometastases in pericolic lymph nodes of Dukes' B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Cancer 1994;73:563-569.
7. Liefers GJ, Cleton-Janson AM, Van de Velde CJH, et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998;339:223-228.
8. Izbicki JR, Hosch SB, Pichlmeier U, et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 1997;337:1188-1194.
9. Hosch SB, Knoefel WT, Metz S, et al. Early lymphatic tumor cell dissemination in pancreatic cancer: Frequency and prognostic significance. Pancreas 1997;15:154-159.
10. Lindemann F, Schlimok G, Dirschedl P, et al. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 1992;19:685-691.
11. Trojani M, de Mascarel I, Bonichon F, et al. Micrometastases to axillary lymph nodes from carcinoma of breast: Detection by immunohistochemistry and prognostic significance. Br J Cancer 1987;55:303-306.
12. Passlick B, Izbicki JR, Kubuschok B, et al. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol 1994;12:1827-1832.
13. Thorban S, Roder JD, Nekarda H, et al. Disseminated epithelial tumor cells in bone marrow of patients with esophageal cancer: Detection and prognostic significance. World J Surg 1996;20:567-573.
14. Laurie JA, Moertel CG, Fleming T, et al. Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of lavamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989;7:1447-1456.
15. Moertel CG, Fleming TR, MacDonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-358.
16. Richard S, Farrell CA, Shaw AS, Showell HJ, Connelly PA. C5a as a model for chemotactic factor-stimulated tyrosine phosphorylation in the human neutrophil. J Immunol 1994; 152:2479-2487.
17. Juhl H, Helmig F, Baltzer K, Kalthoff H, Henne-Bruhns D, Kremer B. Frequent expression of complement resistant factors CD46, CD55 and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A. J Surg Oncol 1997;64:222-230.
18. Nicholson-Weller A, Wang CE. Structure and function of decay accelerating factor CD55. J Lab Clin Med 1994;123:485-491.
19. Morgan BP, Meri S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 1994;15: 369-396.
20. Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal liver metastases: A multi-institutional study of patterns of recurrence. Surgery 1986;100:278-284.
21. Sidransky E. Nucleic acid-based methods for detection of cancer. Science 1997;278:1054-1059.
22. Pantel K, Schlimok G, Braun S, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993;85:1419-1424.
23. Riethmuller G, Schneider-Gädicke E, Johnson JP. Monoclonal antibodies in cancer therapy. Curr Opin Immunol 1993; 5:732-739.
24. Dillman RO. The human antimouse response. Antibody Immunocon Radiopharm 1990;3:1-15.
25. Buchler M, Friess H, Malfertheiner P, et al. Studies of pancreatic cancer utilizing monoclonal antibodies. Int J Pancreatol 1990;7:151-157.
26. Buchler M, Friess H, Schultheiss KH, et al. A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer. Cancer 1991;68:1507-1512.
27. Sears HF, Mattis J, Herlyn D, et al. Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1982;1:762-765.
28. Sears HF, Herlyn D, Steplewski Z, Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 1985;45:5910-5913.
29. Mellstedt H, Frödin JE, Masucci G, et al. The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol 1991;2:462-477.
30. Shaw DR, Khazaeli MB, Sun KL, et al. Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen. J Immunol 1987;138: 4534-4538.
31. Herlyn D, Steplewski Z, Herlyn MKH. Colorectal carcinoma specific antigen: Detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 1979;76:1438-1442.
32. Cheung N-KV, Walter EI, Smith-Mensah WH, et al. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest 1988;81: 1122-1128.
33. Riethmüller G, Schneider-Gädicke E, Schlimok G, et al. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994;343: 1172-1183.
34. Bosslet K, Keveloh H, Hermentin P, et al. Percolation and binding of monoclonal antibody BW 494 to pancreatic carcinoma tissues during high dose immunology and consequences for future therapy modalities. Br J Cancer 1990;10: 37-39.
35. Murphy P, Alexander P, Kirkham N, et al. Pattern of spread of bloodborne tumour. Br J Surg 1986;73:829-836.